Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/180647
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Pachón-Ibáñez, M. E. | es_ES |
dc.contributor.author | Labrador-Herrera, Gema | es_ES |
dc.contributor.author | Cebrero-Cangueiro, Tania | es_ES |
dc.contributor.author | Díaz, Caridad | es_ES |
dc.contributor.author | Smani, Younes | es_ES |
dc.contributor.author | Palacio, José P. del | es_ES |
dc.contributor.author | Rodríguez-Baño, Jesús | es_ES |
dc.contributor.author | Pascual, Álvaro | es_ES |
dc.contributor.author | Pachón, Jerónimo | es_ES |
dc.contributor.author | Conejo, M. Carmen | es_ES |
dc.date.accessioned | 2019-04-26T12:27:55Z | - |
dc.date.available | 2019-04-26T12:27:55Z | - |
dc.date.issued | 2018-05-15 | - |
dc.identifier.citation | Frontiers in Microbiology 9: 912 (2018) | es_ES |
dc.identifier.uri | http://hdl.handle.net/10261/180647 | - |
dc.description.abstract | Despite the relevance of carbapenemase-producing Klebsiella pneumoniae (CP-Kp) infections there are a scarce number of studies to evaluate in vivo the efficacy of combinations therapies. The bactericidal activity of colistin, rifampin, and its combination was studied (time–kill curves) against four clonally unrelated clinical isolates of CP-Kp, producing VIM-1, VIM-1 plus DHA-1(acquired AmpC β-lactamase), OXA-48 plus CTX-M-15 (extended spectrum β-lactamase) and KPC-3, respectively, with colistin MICs of 0.5, 64, 0.5, and 32 mg/L, respectively. The efficacies of antimicrobials in monotherapy and in combination were tested in a murine peritoneal sepsis model, against all the CP-Kp. Their efficacies were tested in the pneumonia model against the OXA-48 plus CTX-M-15 producers. The development of colistin-resistance was analyzed for the colistin-susceptible strains in vitro and in vivo. In vitro, colistin plus rifampin was synergistic against all the strains at 24 h. In vivo, compared to the controls, rifampin alone reduced tissue bacterial concentrations against VIM-1 and OXA-48 plus CTX-M-15 strains; CMS plus rifampin reduced tissue bacterial concentrations of these two CP-Kp and of the KPC-3 strain. Rifampin and the combination increased the survival against the KPC-3 strain; in the pneumonia model, the combination also improved the survival. No resistant mutants appeared with the combination. In conclusion, CMS plus rifampin had a low and heterogeneous efficacy in the treatment of severe peritoneal sepsis model due to CP-Kp producing different carbapenemases, increasing survival only against the KPC-3 strain. The combination showed efficacy in the less severe pneumonia model. The combination prevented in vitro and in vivo the development of colistin resistant mutants. | es_ES |
dc.description.sponsorship | This study was supported by the Consejería de Salud of the Junta de Andalucía (PI-0622-2012) and supported by Plan Nacional de I+D+i and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015/0001) – co-financed by European Development Regional Fund “A way to achieve Europe” ERDF. The MEDINA authors disclosed the receipt of financial support from Fundación MEDINA, a public-private partnership of Merck Sharp & Dohme de España S.A./Universidad de Granada/Junta de Andalucía. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Frontiers Media | es_ES |
dc.relation.isversionof | Publisher's version | es_ES |
dc.rights | openAccess | es_ES |
dc.subject | Klebsiella pneumoniae | es_ES |
dc.subject | Animal models | es_ES |
dc.subject | Carbapenemase producers | es_ES |
dc.subject | Colistin | es_ES |
dc.subject | Rifampin | es_ES |
dc.title | Efficacy of Colistin and Its Combination With Rifampin in Vitro and in Experimental Models of Infection Caused by Carbapenemase-Producing Clinical Isolates of Klebsiella pneumoniae | es_ES |
dc.type | artículo | es_ES |
dc.identifier.doi | 10.3389/fmicb.2018.00912 | - |
dc.description.peerreviewed | Peer reviewed | es_ES |
dc.relation.publisherversion | https://doi.org/10.3389/fmicb.2018.00912 | es_ES |
dc.identifier.e-issn | 1664-302X | - |
dc.rights.license | http://creativecommons.org/licenses/by/4.0/ | es_ES |
dc.contributor.funder | Junta de Andalucía | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | es_ES |
dc.contributor.funder | European Commission | es_ES |
dc.contributor.funder | Fundación MEDINA | es_ES |
dc.contributor.funder | Red Española de Investigación en Patología Infecciosa | es_ES |
dc.relation.csic | Sí | es_ES |
oprm.item.hasRevision | no ko 0 false | * |
dc.identifier.funder | http://dx.doi.org/10.13039/501100003329 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100004587 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100009153 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100000780 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100011011 | es_ES |
dc.identifier.pmid | 29867823 | - |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | With Fulltext | - |
item.cerifentitytype | Publications | - |
item.openairetype | artículo | - |
item.languageiso639-1 | en | - |
item.grantfulltext | open | - |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
fmicb-09-00912.pdf | 676,45 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
8
checked on 09-abr-2024
SCOPUSTM
Citations
15
checked on 15-abr-2024
WEB OF SCIENCETM
Citations
14
checked on 26-feb-2024
Page view(s)
212
checked on 16-abr-2024
Download(s)
110
checked on 16-abr-2024